Prescribed List: Changes from 1 December 2015:

Information about the publication of Ministerial Decisions

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision
providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 6 November 2015:

Decision Reference: MD-S-2015-0090
Decision Summary Title :	Prescribed List as of 1 Dec 2015		Date of Decision Summary:	6 November 2015
Decision Summary Author:	Prescribing Advisor		Decision Summary: Public or Exempt?	Public
Type of Report: Oral or Written?	Written		Person Giving Oral Report:	N/A
Written Report Title :	PBAC Report of 13 October 2015		Date of Written Report:	6 November 2015
Written Report Author:	Prescribing Advisor		Written Report : Public or Exempt?	Exemption: FoI (J) Law 2011 Part 5 (33) Commercial Interests
Subject: Changes to be made to the Prescribed List (Jersey) as at 1 December 2015
Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List. The Minister approved the following additions to the list Fluticasone furoate/vilanterol (brand name Relvar Ellipta) Umecledinium/vilanterol (brand name Anoro Ellipta) Umecledinium (brand name Incruse Ellipta) Bupenorphine transdermal patch 5mcg/hour, 10mcg/hour (brand name BuTrans) Methenamine hippurate (hexamine hippurate) Teicoplanin injection 200mg, 400mg In addition, the Minister approved new formulations of products already on the Prescribed List Metformin modified-release tablets 500mg, 750mg, 1g for the treatment of type II diabetes mellitus Midazolam (brand name Buccolam) oromucosal solution 2.5mg, 5mg, 7.5mg, 10mg in pre-filled syringe for [unlicensed] use in palliative care only Desmopressin 60mcg, 120mcg, 240mcg oral lyophilisates (‘melt’) tablets for sublingual use – for the treatment of adults and children with diabetes insipidus or nocturnal enuresis The Minister also approved removal of the following products from the Prescribed List Bimatoprost 300mcg/mL (3mL) multidose eye drops Salbutamol m/r 4mg, 8mg capsules Magnesium hydroxide with liquid paraffin liquid The Minister also approved that the following patent expired medicines should be included on the Prescribed list as ‘Generic Only’ items. Oxycodone capsules 5mg, 10mg, 20mg; modified-release tablets 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg,120mg Salmeterol/fluticasone pressurised metered-dose inhaler 25mcg/50mcg, 25mcg/125mcg, 25mcg/250mcg The Minister accepted recommendations to make the following minor amendments to the prescribed list Peppermint oil capsules – to amend text to include both e/c and e/c m/r products Carbomer 981 liquid eye gel - to amend text to carbomer 980 liquid eye gel Finally the Minister accepted the recommendation to add Co-cyprindiol tablets 2mg/35mcg (for the treatment of acne in women requiring contraception) to the list of medicines that can be supplied in quantities of up to 90-days Additions to the Prescribed List will be effective from 1 December 2015. Where items are to be removed from the List or to be listed by generic name only, this will be effective from 1 January 2016 and prescriptions for these products will be reimbursed until 29 February 2016. The addition of Co-cyprindiol tablets 2mg/35mcg to the 90 day list will be made by order, coming into effect one week after that Order has been made.
Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee (PBAC) met on 13 October 2015 and has provided the Minister with the accompanying written report setting out its recommendations in respect of amendments to the Prescribed List. The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund.
Resource Implications: The overall impact of the changes represents an anticipated increase in expenditure of £18,000 to the Health Insurance fund
Action required: Policy Principal to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.
Signature:		Position: Minister
Date Signed:		Date of Decision (If different from Date Signed):